How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
46
AMPH Quote, Financials, Valuation and Earnings
Last price:
$26.17
Seasonality move
:
-1.02%
Day range:
$25.86 - $26.45
52-week range:
$20.39 - $37.28
Dividend yield:
0%
P/E ratio:
11.58x
P/S ratio:
1.78x
P/B ratio:
1.55x
Volume:
209K
Avg. volume:
348.1K
1-year change:
-29.63%
Market cap:
$1.2B
Revenue:
$732M
EPS (TTM):
$2.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$190.5M | $0.92 | 1.61% | 56.77% | $31.71 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$142.8M | $0.59 | 1.73% | 35.24% | $34.57 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.80 | 195.3% | 90.44% | $14.86 |
|
LLY
Eli Lilly & Co.
|
$18B | $6.95 | 35.51% | 147.92% | $1,133.93 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.88% | 43.64% | $28.78 |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$195.6M | $0.40 | 29.51% | 45.49% | $61.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$26.12 | $31.71 | $1.2B | 11.58x | $0.00 | 0% | 1.78x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$24.20 | $34.57 | $3B | 14.12x | $0.00 | 0% | 5.31x |
|
CRMD
CorMedix, Inc.
|
$7.75 | $14.86 | $610.6M | 3.77x | $0.00 | 0% | 2.61x |
|
LLY
Eli Lilly & Co.
|
$1,023.80 | $1,133.93 | $916.3B | 50.63x | $1.50 | 0.59% | 15.71x |
|
PFE
Pfizer Inc.
|
$25.86 | $28.78 | $147B | 15.07x | $0.43 | 6.65% | 2.35x |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$48.94 | $61.33 | $2.8B | 41.17x | $0.00 | 0% | 4.05x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
45.82% | 0.275 | 53.17% | 2.07x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
0.31% | -0.785 | 0.12% | 6.19x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.496 | 6.22% | 0.65x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
3.87% | 0.793 | 1.55% | 1.37x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$95M | $25.3M | 7.98% | 14.9% | 13.2% | $47.2M |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$116.4M | $66.3M | 27.37% | 27.48% | 44.66% | $32.4M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$148.3M | -$61M | -1.78% | -1.84% | -31.77% | -$61.8M |
Amphastar Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns AMPH or CPRX?
Catalyst Pharmaceuticals, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 35.57%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B CPRXCatalyst Pharmaceuticals, Inc.78.44% $0.42 $923.1M -
What do Analysts Say About AMPH or CPRX?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 20.87%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.57 which suggests that it could grow by 42.86%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 CPRXCatalyst Pharmaceuticals, Inc.7 0 0 -
Is AMPH or CPRX More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.894, which suggesting that the stock is 10.551% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.786%.
-
Which is a Better Dividend Stock AMPH or CPRX?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or CPRX?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.58x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.78x versus 5.31x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.78x 11.58x $191.8M $17.4M CPRXCatalyst Pharmaceuticals, Inc.5.31x 14.12x $148.4M $52.8M
-
Which has Higher Returns AMPH or CRMD?
CorMedix, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 49.9%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About AMPH or CRMD?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 20.87%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 91.71%. Given that CorMedix, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 CRMDCorMedix, Inc.4 0 0 -
Is AMPH or CRMD More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.894, which suggesting that the stock is 10.551% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock AMPH or CRMD?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or CRMD?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.58x while CorMedix, Inc.'s PE ratio is 3.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.78x versus 2.61x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.78x 11.58x $191.8M $17.4M CRMDCorMedix, Inc.2.61x 3.77x $104.3M $108.6M
-
Which has Higher Returns AMPH or LLY?
Eli Lilly & Co. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 31.72%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About AMPH or LLY?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 20.87%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,133.93 which suggests that it could grow by 10.76%. Given that Amphastar Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Amphastar Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 LLYEli Lilly & Co.18 7 0 -
Is AMPH or LLY More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.894, which suggesting that the stock is 10.551% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.
-
Which is a Better Dividend Stock AMPH or LLY?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AMPH or LLY?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.58x while Eli Lilly & Co.'s PE ratio is 50.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.78x versus 15.71x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.78x 11.58x $191.8M $17.4M LLYEli Lilly & Co.15.71x 50.63x $17.6B $5.6B
-
Which has Higher Returns AMPH or PFE?
Pfizer Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 21.32%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About AMPH or PFE?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 20.87%. On the other hand Pfizer Inc. has an analysts' consensus of $28.78 which suggests that it could grow by 11.3%. Given that Amphastar Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Amphastar Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 PFEPfizer Inc.7 15 1 -
Is AMPH or PFE More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.894, which suggesting that the stock is 10.551% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock AMPH or PFE?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.65% to investors and pays a quarterly dividend of $0.43 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or PFE?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.58x while Pfizer Inc.'s PE ratio is 15.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.78x versus 2.35x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.78x 11.58x $191.8M $17.4M PFEPfizer Inc.2.35x 15.07x $16.7B $3.6B
-
Which has Higher Returns AMPH or SUPN?
Supernus Pharmaceuticals, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of -23.49%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Supernus Pharmaceuticals, Inc.'s return on equity of -1.84%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B -
What do Analysts Say About AMPH or SUPN?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.71, signalling upside risk potential of 20.87%. On the other hand Supernus Pharmaceuticals, Inc. has an analysts' consensus of $61.33 which suggests that it could grow by 25.32%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 SUPNSupernus Pharmaceuticals, Inc.4 1 0 -
Is AMPH or SUPN More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.894, which suggesting that the stock is 10.551% less volatile than S&P 500. In comparison Supernus Pharmaceuticals, Inc. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.701%.
-
Which is a Better Dividend Stock AMPH or SUPN?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Supernus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or SUPN?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Supernus Pharmaceuticals, Inc. quarterly revenues of $192.1M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than Supernus Pharmaceuticals, Inc.'s net income of -$45.1M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 11.58x while Supernus Pharmaceuticals, Inc.'s PE ratio is 41.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.78x versus 4.05x for Supernus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.78x 11.58x $191.8M $17.4M SUPNSupernus Pharmaceuticals, Inc.4.05x 41.17x $192.1M -$45.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
